TSHR Molekülinformation
Molecule Name
Thyroid stimulating hormone receptor
Molekülalias
TSHR,TSH-R,LGR3,TSH R
Drug Development Progress
Anzahl der klinischen Arzneimittel6
Anzahl der inverkehr gebrachten Arzneimittel3
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
TSHR，Thyroid Stimulating Hormone Receptor，LGR3，Thyroid-Stimulating Hormone Receptor，Seven Transmembrane Helix Receptor，Thyrotropin Receptor-I， HTSHR-I，Thyrotropin Receptor，TSH Receptor，HTSHR-I，TSH-R，Receptors， Thyrotropin，CHNG1
Molekülhintergrund
The protein encoded by this gene is a membrane protein and a major controller of thyroid cell metabolism. The encoded protein is a receptor for thyrothropin and thyrostimulin, and its activity is mediated by adenylate cyclase. Defects in this gene are a cause of several types of hyperthyroidism. Three transcript variants encoding different isoforms have been found for this gene.
TSHR Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Anti-thyroid stimulating hormone receptor chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) | ICTCAT-023 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Thyroid Neoplasms | Details |
| ZG-001(Zhigen) | ZG-001(Zhigen); JH-001 | Phase 2 Clinical | Hunan Warner Pharmaceutical Factory Chiral Medicine Co Ltd, Hunan Warrant Pharmaceutical Co Ltd, Shanghai Zhigen Pharmaceutical Technology Co Ltd | Depressive Disorder; Depressive Disorder, Major | Details |
| ICTCAR-051 | ICTCAR-051 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Solid tumours; Thyroid Neoplasms | Details |
| KSP-0914 | Phase 1 Clinical | Kissei Pharmaceutical Co Ltd | Graves Disease | Details | |
| GensSci098 | GenSci098; GenSci-098; GensSci-098; GensSci098; GS-098; YB-101 | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Goiter; Graves Disease; Graves Ophthalmopathy | Details |
| ICTCAR-TC | ICTCAR-TC | Clinical | Innovative Cellular Therapeutics Co Ltd | Thyroid Neoplasms | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Thyrotropin alfa | rh-TSH; MRrhTSH; rhTSH-M | Approved | Genzyme Corp | Thyrogen | United States | Thyroid Neoplasms | Genzyme Corp | 1998-11-30 | Diagnostic agents; Goiter, Nodular; Thyroid Neoplasms | Details |
| Recombinant human thyrotropin (Zelgen Biosciences) | Approved | Suzhou Zelgen Biosciences Co Ltd | 赛诺璟, 泽速宁 | Mainland China | Thyroid Neoplasms | Suzhou Zelgen Biopharmaceuticals Co Ltd | 2026-01-05 | Thyroid Neoplasms | Details | |
| Recombinant human thyroid stimulating hormone(Smartnuclide) | SNA-001; SNA001; KN040; KN-040 | Approved | Smartnuclide Biopharma | 智舒嘉 | Mainland China | Thyroid Neoplasms | Smartnuclide Biopharma | 2024-04-02 | Thyroid Neoplasms | Details |